Stockreport

MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook [Seeking Alpha]

MaxCyte, Inc.  (MXCT) 
PDF Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired [Read more]